Angiotensin Fragment 1-7 (acetate)
目录号 : GC12671
A type 1 angiotensin II receptor agonist
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Angiotensin Fragment 1-7 is a type 1 angiotensin II receptor agonist.
In the renin-angiotensin system, angiotensin I is cleaved by angiotensin-converting enzyme to form angiotensin II, which has effects on fluid and electrolyte, as well as homeostasis blood pressure.
In vitro: In a previous study, peripheral atherectomy plaques collected from diabetic (DM) and 12 non-DM patients were immunostained. Results showed that the tissue contents of ACE2, angiotensin fragment 1-7, and AT1R were increased in DM when compared to non-DM. IL-6 and TNF-α were also increased in DM when compared to non-DM, as well as macrophage infiltration score and neovessel counting [1].
In vivo: The effects of chronic angiotensin fragment 1-7 treatment was studied in an experimental model of the metabolic syndrome, rats given high-fructose/low-magnesium diet (HFrD). After 6 months, angiotensin fragment 1-7-treated animals had lower body weight, total fat mass, and serum triglycerides, improved glucose tolerance, and better insulin sensitivity. Similar metabolic effects were also evident, albeit in the absence of weight loss, in rats first exposed to HFrD for 5 months and then subjected to short-term treatment with angiotensin fragment 1-7 [2].
Clinical trial: So far, no clinical study has been conducted.
References:
[1] Purushothaman, K. R.,Krishnan, P.,Purushothaman, M., et al. Expression of angiotensin-converting enzyme 2 and its end product angiotensin 1-7 is increased in diabetic atheroma: Implications for inflammation and neovascularization. Cardiovascular Pathology 22, 42-48 (2013).
[2] Marcus, Y. ,Shefer, G.,Sasson, K., et al. Angiotensin 1-7 as means to prevent the metabolic syndrome: Lessons from the fructose-fed model. Diabetes 62, 1121-1130 (2013).
| Cas No. | SDF | ||
| 化学名 | 5-L-isoleucine-1-7-angiotensin II | ||
| Canonical SMILES | O=C([C@H](CC1=CNC=N1)NC([C@@]([H])(NC([C@H](CC2=CC=C(C=C2)O)NC([C@@H](NC([C@@H](NC([C@H](CC(O)=O)N)=O)CCCNC(N)=N)=O)C(C)C)=O)=O)[C@H](CC)C)=O)N3CCC[C@H]3C(O)=O.CC(O)=O | ||
| 分子式 | C41H62N12O11 • XC2H4O2 | 分子量 | 899 |
| 溶解度 | ≤10mg/ml in PBS | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.1123 mL | 5.5617 mL | 11.1235 mL |
| 5 mM | 0.2225 mL | 1.1123 mL | 2.2247 mL |
| 10 mM | 0.1112 mL | 0.5562 mL | 1.1123 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet